Want to see PYXS full AI Analyst Report?
PYXS Stock Chart & Stats
$2.61
$0.30(11.49%)
At close: 4:00 PM EDT
$2.61
$0.30(11.49%)
Day’s Range― - ―
52-Week Range$0.97 - $5.55
Previous CloseN/A
Volume197.33K
Average Volume (3M)757.02K
Market Cap
$184.36M
Enterprise Value$68.43
Total Cash (Recent Filing)$42.49M
Total Debt (Recent Filing)$18.26M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 19, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding63,355,480
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside149.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.22
Revenue Forecast (FY)$58.33K
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway From FinancingThe completed private placement materially strengthens near-term liquidity, extending runway into Q2 2027. That funding reduces immediate financing pressure, allowing continued clinical development and data generation without imminent dilution, supporting execution of planned MICVO trials.
Board And Audit Governance StabilityElection of experienced directors and ratification of a Big Four auditor improve governance and financial oversight. Strong governance lowers operational and reporting risk, bolstering credibility with investors and partners as the company advances clinical programs and seeks further capital.
Focused Clinical-Stage Oncology PipelineA targeted pipeline in immuno-oncology and ADCs addresses high unmet need and can create durable value if trials succeed. Scheduled MICVO monotherapy and combo readouts in 2026 provide structured milestones that can de-risk programs and catalyze partner or payer interest over the medium term.
Bears Say
High And Persistent Cash BurnSustained negative operating and free cash flow near -$67M TTM indicates ongoing funding dependence. Even with recent financing, persistent cash burn raises the probability of future dilutive financings or program delays if clinical costs remain elevated and milestones or non-dilutive funding sources aren't secured.
Sharply Contracted Equity BaseA materially smaller equity base and shrinking assets reduce the company's financial cushion against shocks. This erosion limits balance-sheet flexibility, increases creditor and investor sensitivity to execution risk, and elevates dilution risk when new capital is required for development programs.
Declining And Non‑Recurring RevenueRevenue contraction and reliance on non-recurring milestone/license receipts indicate limited durable commercial traction. Without recurring revenue streams, the company must rely on external funding and clinical success to sustain operations, making long-term financial predictability weak.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.97 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $184.36M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Aug 19, 2026 which is in 21 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on May 14, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.364 by -$0.006.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.34.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 63,355,480 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.364. Following the earnings report the stock price went down -15.649%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pyxis Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (149.04% Upside)
$6.50 (149.04% Upside)
Hedge Fund Trend
Decreased
By 161.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.67%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.50
▲(149.04% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
2.81% Insiders
4.05% Mutual Funds
1.55% Other Institutional Investors
87.35% Public Companies and
Individual Investors